EGFR and non-small cell lung carcinoma: In this real-world clinical study, systemic and local treatment outcomes of patients with BMs were retrospectively analyzed focusing on EGFRm + NSCLC combined with BMs cases and included 1st generation EGFR-TKI treatment alone and 1st generation EGFR-TKI plus chemotherapy or anti-angiogenesis drugs.